PersonGen

PersonGen BioTherapeutics (Suzhou) Co., Ltd. was registered and established in the Suzhou Industrial Park on May 31, 2010. "PersonGen," an abbreviation for "Personalized Gene Therapy," reflects the company's commitment to the research, development, and innovation of personalized medical technologies. Led by Dr. Yang Lin, the company was co-founded by a team of biomedical experts with over ten years of experience at top overseas cancer clinical treatment and research institutions. As a high-tech enterprise, its primary development goal is the advancement of breakthrough tumor cell immunotherapy technologies and product development. The company has successively received numerous honors and qualifications, including ISO 9001:2008 International Quality Management System Certification, Jiangsu Province Private Science and Technology Enterprise, Jiangsu Province Double Innovation Talent Plan Enterprise, Suzhou Gusu Leading Talent for Innovation and Entrepreneurship Enterprise, Suzhou Industrial Park Science and Technology Leading Talent Enterprise, Jiangsu Province Six Major Talent Peaks Team, and National High-Tech Enterprise. Additionally, the company has established R&D platforms such as a Postdoctoral Incubation Workstation and the "Suzhou Tumor Immunodiagnosis and Treatment Engineering Technology Research Center."Over the past decade since its establishment, PersonGen has built a first-class R&D team characterized by high standards and strong professional expertise, with individuals holding doctoral or master’s degrees comprising more than 80% of the R&D staff. The team has published over 30 research papers in prestigious journals such as *Cancer Cell*, *Cancer Research*, *Oncogene*, and *Cancer Science*. The company has filed more than 30 domestic and international invention patents, with over 10 patents granted. It also holds 18 registered trademarks (16 authorized). Thirteen CAR-T and CAR-NK clinical trials have been registered on the international clinical trial registry ClinicalTrials.gov, and formal clinical studies have been conducted at more than ten partner hospitals.The company’s R&D center and laboratories are located in the BioBAY of the Suzhou Industrial Park, equipped with comprehensive cell therapy and molecular biology facilities. These capabilities support the development of world-class new cell therapy technologies, covering antigen-binding domain development, CAR structure optimization, functional testing of CAR-T cells, and validation through in vivo efficacy studies. PersonGen possesses advanced platforms for CAR structure and functional validation, in vivo efficacy validation of CAR-T cells, Safeγ UCAR-γδT cell drug development, and NanoBa bispecific antibody R&D. The company focuses on developing breakthrough First-in-class and Best-in-class CAR-T cell drugs with internationally leading standards. Multiple cell therapy products have entered the Proof-of-Concept (POC) clinical validation stage, covering most hematologic malignancies and some solid tumors. Furthermore, PersonGen is actively developing bispecific antibody drugs and is committed to becoming a global leader in CAR-T cell therapies, thereby benefiting a broad population of cancer patients.